NASDAQ:EXAS - Exact Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $71.00
  • Forecasted Upside: 67.61 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$42.36
▼ -2.77 (-6.14%)

This chart shows the closing price for EXAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exact Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

Analyst Price Target is $71.00
▲ +67.61% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $71.00, with a high forecast of $130.00 and a low forecast of $50.00. The average price target represents a 67.61% upside from the last price of $42.36.

This chart shows the closing price for EXAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 polled investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/17/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/12/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/11/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Evercore ISIBoost Price Target$65.00N/A
8/9/2022BenchmarkLower Price Target$54.00N/A
8/3/2022Raymond JamesLower Price TargetOutperform$80.00 ➝ $70.00Low
8/3/2022CitigroupLower Price TargetNeutral$65.00 ➝ $50.00Low
8/3/2022Robert W. BairdLower Price TargetOutperform$90.00 ➝ $75.00Low
8/3/2022BTIG ResearchLower Price TargetBuy$100.00 ➝ $70.00Low
8/3/2022CowenLower Price TargetOutperform$83.00 ➝ $67.00N/A
8/3/2022CowenLower Price TargetOutperform$83.00 ➝ $67.00Low
8/3/2022Craig HallumLower Price TargetBuy$81.00 ➝ $60.00Low
7/19/2022CowenSet Price Target$83.00Low
6/2/2022Piper SandlerInitiated CoverageNeutral$50.00High
4/27/2022Craig HallumLower Price Target$100.00 ➝ $81.00Low
4/27/2022Robert W. BairdLower Price Target$100.00 ➝ $90.00High
4/27/2022Raymond JamesLower Price Target$90.00 ➝ $80.00High
4/27/2022CitigroupLower Price Target$80.00 ➝ $65.00High
4/19/2022The Goldman Sachs GroupLower Price TargetBuy$100.00 ➝ $85.00Low
2/23/2022Craig HallumLower Price Target$133.00 ➝ $100.00High
2/23/2022Raymond JamesLower Price TargetOutperform$130.00 ➝ $90.00High
2/23/2022Wells Fargo & CompanyLower Price TargetEqual Weight$95.00 ➝ $80.00High
2/23/2022Robert W. BairdLower Price Target$116.00 ➝ $100.00High
2/23/2022CitigroupLower Price TargetNeutral$100.00 ➝ $80.00High
2/23/2022SVB LeerinkLower Price TargetOutperform$140.00 ➝ $130.00High
11/3/2021BTIG ResearchLower Price TargetPositive ➝ Buy$145.00 ➝ $120.00High
11/3/2021Craig HallumLower Price TargetBuy$144.00 ➝ $133.00High
11/3/2021SVB LeerinkLower Price TargetOutperform$160.00 ➝ $140.00High
11/3/2021Wells Fargo & CompanyLower Price TargetEqual Weight$120.00 ➝ $95.00High
11/3/2021Robert W. BairdLower Price TargetOutperform$125.00 ➝ $116.00High
11/3/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$160.00 ➝ $130.00High
10/14/2021CowenLower Price TargetOutperform$160.00 ➝ $135.00Low
7/29/2021Stifel NicolausLower Price TargetBuy$165.00 ➝ $145.00High
7/29/2021BTIG ResearchLower Price TargetBuy$155.00 ➝ $145.00High
7/29/2021OppenheimerLower Price TargetOutperform$161.00 ➝ $155.00High
7/29/2021Robert W. BairdLower Price TargetOutperform$157.00 ➝ $127.00High
7/14/2021SVB LeerinkLower Price TargetOutperform$170.00 ➝ $160.00High
6/21/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$115.00 ➝ $120.00Low
6/15/2021Raymond JamesInitiated CoverageStrong-Buy$160.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$115.00Low
5/12/2021Truist FinancialLower Price TargetBuy$226.00 ➝ $168.00Medium
5/5/2021Craig HallumLower Price TargetBuy$161.00 ➝ $144.00High
5/5/2021BTIG ResearchLower Price TargetBuy$175.00 ➝ $155.00High
5/5/2021SVB LeerinkLower Price TargetOutperform$180.00 ➝ $170.00High
2/18/2021Robert W. BairdLower Price TargetOutperform$169.00 ➝ $163.00Low
2/17/2021Stifel NicolausBoost Price TargetBuy$150.00 ➝ $165.00Low
2/17/2021SVB LeerinkBoost Price TargetMarket Perform ➝ Outperform$170.00 ➝ $180.00Low
2/17/2021CowenBoost Price TargetOutperform$154.00 ➝ $180.00Low
1/27/2021Truist FinancialInitiated CoverageBuy$226.00 ➝ $226.00Medium
1/21/2021SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $170.00Medium
10/29/2020UBS GroupDowngradeBuy ➝ Neutral$125.00 ➝ $140.00High
10/28/2020OppenheimerBoost Price Target$115.00 ➝ $150.00Low
10/28/2020BTIG ResearchBoost Price Target$140.00 ➝ $155.00Low
10/28/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $140.00Low
10/28/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$135.00 ➝ $150.00Low
10/28/2020SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $160.00Low
10/28/2020BenchmarkBoost Price TargetBuy$110.00 ➝ $145.00Low
7/31/2020SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $115.00High
7/31/2020BenchmarkBoost Price TargetBuy$90.00 ➝ $110.00Low
7/31/2020CitigroupBoost Price TargetBuy$110.00 ➝ $120.00Low
7/8/2020OppenheimerReiterated RatingBuyHigh
6/25/2020CitigroupBoost Price TargetBuy$100.00 ➝ $110.00Medium
5/7/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $92.00Low
5/7/2020Bank of AmericaBoost Price TargetBuy$88.00 ➝ $94.00Low
5/7/2020Craig HallumLower Price TargetIn-Line ➝ Buy$99.00 ➝ $92.00Low
5/7/2020SVB LeerinkLower Price TargetOutperform$100.00 ➝ $90.00High
4/28/2020UBS GroupLower Price TargetBuy$135.00 ➝ $115.00High
4/22/2020CitigroupLower Price TargetBuy$120.00 ➝ $100.00Medium
4/22/2020Robert W. BairdLower Price TargetOutperform$100.00 ➝ $90.00High
4/21/2020OppenheimerReiterated RatingBuy$115.00Low
4/17/2020Craig HallumLower Price TargetBuy$127.00 ➝ $99.00High
4/2/2020Stifel NicolausLower Price TargetBuy$110.00 ➝ $90.00Low
4/2/2020Evercore ISIInitiated CoverageOutperform$70.00High
2/14/2020Stifel NicolausReiterated RatingBuy$110.00N/A
2/12/2020Robert W. BairdReiterated RatingBuyLow
1/10/2020BTIG ResearchInitiated CoverageBuy$127.00High
1/6/2020CitigroupInitiated CoverageBuy$120.00Low
12/13/2019Dougherty & CoInitiated CoverageBuy$120.00Low
11/14/2019Stifel NicolausInitiated CoverageBuy$110.00High
10/31/2019Bank of AmericaReiterated RatingBuy$135.00Medium
10/30/2019SVB LeerinkLower Price TargetOutperform$133.00 ➝ $105.00Medium
10/30/2019Jefferies Financial GroupLower Price TargetBuy$138.00 ➝ $120.00High
10/17/2019Bank of AmericaBoost Price TargetBuy$130.00 ➝ $135.00Low
9/26/2019OppenheimerInitiated CoverageOutperform$130.00Medium
9/24/2019SVB LeerinkReiterated RatingBuyHigh
9/23/2019BenchmarkUpgradeHold ➝ Buy$130.00High
9/10/2019William BlairReiterated RatingBuyLow
8/1/2019UBS GroupBoost Price TargetBuy$120.00 ➝ $143.00Low
7/30/2019Craig HallumBoost Price TargetBuy$115.00 ➝ $127.00Medium
7/29/2019CowenBoost Price TargetOutperform$125.00 ➝ $135.00Low
5/1/2019Jefferies Financial GroupBoost Price TargetBuy$100.00 ➝ $115.00Low
5/1/2019UBS GroupBoost Price TargetBuy ➝ Buy$115.00 ➝ $120.00Low
5/1/2019Craig HallumReiterated RatingBuy$95.00 ➝ $115.00Low
5/1/2019BTIG ResearchBoost Price TargetBuy$130.00Low
4/16/2019UBS GroupBoost Price TargetBuy ➝ Buy$109.00 ➝ $115.00Low
2/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$85.00 ➝ $120.00Medium
2/22/2019UBS GroupSet Price TargetBuy$109.00Low
2/22/2019Craig HallumSet Price TargetIn-Line ➝ Buy$77.00 ➝ $95.00High
2/22/2019BTIG ResearchBoost Price TargetBuy ➝ Positive$110.00High
2/21/2019Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $102.00High
1/28/2019UBS GroupBoost Price TargetBuy$100.00 ➝ $109.00Medium
1/7/2019William BlairReiterated RatingOutperformHigh
11/29/2018UBS GroupSet Price TargetBuy$100.00Low
10/31/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$74.00 ➝ $84.00Low
10/30/2018UBS GroupSet Price TargetBuy$100.00High
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$100.00Low
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$74.00 ➝ $85.00Low
9/6/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$68.00 ➝ $92.00Medium
9/5/2018CowenBoost Price TargetOutperform$65.00 ➝ $100.00High
9/5/2018BenchmarkReiterated RatingHold ➝ HoldHigh
8/30/2018The Goldman Sachs GroupBoost Price TargetNeutral$75.00Low
8/23/2018Craig HallumBoost Price TargetBuy$54.00 ➝ $74.00Medium
8/23/2018Jefferies Financial GroupReiterated RatingBuy$74.00High
8/23/2018SVB LeerinkReiterated RatingOutperform$90.00High
8/23/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $74.00High
8/22/2018BTIG ResearchBoost Price TargetBuy$95.00High
8/2/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$60.00 ➝ $57.00High
8/2/2018Bank of AmericaLower Price TargetBuy ➝ Buy$75.00 ➝ $68.00High
8/2/2018Craig HallumLower Price TargetBuy$60.00 ➝ $54.00High
7/23/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$67.00 ➝ $75.00Medium
7/18/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$67.00 ➝ $76.00Low
7/9/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $70.00Low
6/18/2018CowenBoost Price TargetOutperform$65.00 ➝ $85.00Low
6/5/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $66.00Medium
6/5/2018BTIG ResearchReiterated RatingBuyMedium
5/30/2018BTIG ResearchBoost Price TargetPositive ➝ Buy$60.00 ➝ $70.00High
4/29/2018BTIG ResearchReiterated RatingBuy$60.00High
4/3/2018BTIG ResearchUpgradeNeutral ➝ BuyLow
3/29/2018William BlairReiterated RatingBuyN/A
3/28/2018SVB LeerinkSet Price TargetBuy$67.00High
2/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$42.56 ➝ $56.00Medium
2/23/2018SVB LeerinkSet Price TargetBuy$67.00High
2/23/2018BenchmarkDowngradeBuy ➝ HoldHigh
2/9/2018SVB LeerinkSet Price TargetBuy$67.00Medium
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.77 ➝ $51.00Low
1/17/2018BenchmarkSet Price TargetBuy$65.00Medium
1/10/2018William BlairReiterated RatingBuyHigh
1/8/2018Bank of AmericaSet Price TargetBuy$67.00High
1/2/2018William BlairReiterated RatingBuyLow
11/29/2017Bank of AmericaBoost Price TargetBuy$58.00 ➝ $67.00Low
11/13/2017SVB LeerinkReiterated RatingOutperform$63.00 ➝ $67.00N/A
11/13/2017Robert W. BairdDowngradeOutperform ➝ Neutral$56.00N/A
11/1/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/31/2017Bank of AmericaBoost Price TargetBuy$56.00 ➝ $58.00N/A
10/31/2017Robert W. BairdBoost Price TargetOutperform$49.00 ➝ $56.00N/A
10/31/2017Craig HallumBoost Price TargetBuy$46.00 ➝ $61.00N/A
10/31/2017BenchmarkReiterated RatingBuy ➝ Buy$50.00 ➝ $60.00N/A
10/31/2017SVB LeerinkReiterated RatingOutperform$50.00 ➝ $63.00N/A
10/31/2017Jefferies Financial GroupBoost Price TargetBuy$60.00N/A
10/19/2017Bank of AmericaSet Price TargetBuy$40.00 ➝ $56.00N/A
10/6/2017Robert W. BairdReiterated RatingBuy$49.00N/A
9/21/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$45.00 ➝ $50.00High
8/24/2017SVB LeerinkSet Price TargetBuy$45.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/14/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/13/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/15/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2022
  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/13/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/13/2022
  • 3 very positive mentions
  • 20 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 3 very positive mentions
  • 20 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Exact Sciences logo
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $42.36
Low: $42.07
High: $46.09

50 Day Range

MA: $44.06
Low: $35.61
High: $49.49

52 Week Range

Now: $42.36
Low: $35.34
High: $108.99

Volume

3,884,805 shs

Average Volume

2,129,417 shs

Market Capitalization

$7.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Benchmark Co., BTIG Research, Citigroup Inc., Cowen Inc, Cowen Inc., Craig Hallum, Evercore ISI, Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

13 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $71.00, suggesting a possible upside of 67.6%. SVB Leerink LLC has the highest price target set, predicting EXAS will reach $130.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $50.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 3 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is (608) 284-5700 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com. Learn More about contacing Exact Sciences investor relations.